Skip to main content

Table 3 Univariate and multivariate logistic regression analyses of predictors for discontinuation of anti-TNFα therapy at week 48

From: Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease

 

Univariate analysis

Multivariate analysis

OR

95% CI

p value

OR

95% CI

p value

Sex (male vs. female)

4.9

0.79–30.3

0.09

2.7

0.31–22.7

0.37

Age at disease onset (≥ 40 vs. < 40 years old)

2.0

0.38–10.5

0.41

1.9

0.20–17.5

0.59

Disease duration before anti-TNFα agent initiation (≥ 5 vs. < 5 years)

0.4

0.07–2.7

0.38

0.4

0.04–4.96

0.49

Type of anti-TNFα agent administered (IFX vs. ADA)

0.8

0.15–3.8

0.73

   

CRP level at baseline (≥ 1 vs. < 1 mg/dL)

9.6

1.45–63.5

0.019

10.5

1.21–90.2

0.033

Concomitant use of systemic corticosteroid (≥ 20 mg) (yes vs. no)

1.5

0.27–8.3

0.64

   
  1. ADA, adalimumab; CI, confidence interval; CRP, C-reactive protein; IFX, infliximab; OR, odds ratio; TNFα, tumor necrosis factor α